- Home
- APM vs FEMY Comparison
APM vs FEMY Comparison
Compare APM & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APM
- FEMY
- Stock Information
- Founded
- APM 2010
- FEMY 2004
- Country
- APM United Kingdom
- FEMY United States
- Employees
- APM N/A
- FEMY N/A
- Industry
- APM Biotechnology: Pharmaceutical Preparations
- FEMY Medical/Dental Instruments
- Sector
- APM Health Care
- FEMY Health Care
- Exchange
- APM Nasdaq
- FEMY Nasdaq
- Market Cap
- APM 18.9M
- FEMY 18.6M
- IPO Year
- APM 2018
- FEMY 2021
- Fundamental
- Price
- APM $1.85
- FEMY $0.37
- Analyst Decision
- APM
- FEMY Strong Buy
- Analyst Count
- APM 0
- FEMY 3
- Target Price
- APM N/A
- FEMY $7.33
- AVG Volume (30 Days)
- APM 20.3M
- FEMY 1.6M
- Earning Date
- APM 04-30-2025
- FEMY 08-08-2025
- Dividend Yield
- APM N/A
- FEMY N/A
- EPS Growth
- APM N/A
- FEMY N/A
- EPS
- APM N/A
- FEMY N/A
- Revenue
- APM N/A
- FEMY $1,887,016.00
- Revenue This Year
- APM N/A
- FEMY $103.55
- Revenue Next Year
- APM N/A
- FEMY $148.13
- P/E Ratio
- APM N/A
- FEMY N/A
- Revenue Growth
- APM N/A
- FEMY 98.61
- 52 Week Low
- APM $0.46
- FEMY $0.31
- 52 Week High
- APM $7.49
- FEMY $1.80
- Technical
- Relative Strength Index (RSI)
- APM 50.26
- FEMY 22.96
- Support Level
- APM $2.17
- FEMY $0.31
- Resistance Level
- APM $2.65
- FEMY $0.42
- Average True Range (ATR)
- APM 0.36
- FEMY 0.06
- MACD
- APM -0.05
- FEMY -0.02
- Stochastic Oscillator
- APM 18.38
- FEMY 14.13
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.